# Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)

> **NCT03551730** · PHASE2 · COMPLETED · sponsor: **Portola Pharmaceuticals** · enrollment: 27 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **COMBINATION_PRODUCT:** PRT064445/Enoxaparin
- **COMBINATION_PRODUCT:** Placebo/Enoxaparin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03551730
- **Lead sponsor:** Portola Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2023-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03551730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03551730, "Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03551730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*